ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arbutus Biopharma Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.23+0.01 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $835.30M
- P/E (TTM)
- 5.4
- Dividend yield
- –
Arbutus Biopharma Corp revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from collaborations and licenses | $632.00K | $178.74M | – | – | $0 | $0 | – | – | – | – | – | – | 62.3% | – |
| Collaborations and licenses | $202.00K | $204.00K | $792.00K | $280.00K | $10.21M | $1.32M | $1.06M | $767.00K | $1.16M | $939.00K | $945.00K | $3.94M | 19.9% | -98.0% |
| Non-cash royalty revenue | $180.00K | $181.00K | $259.00K | $249.00K | $526.00K | $448.00K | $516.00K | $572.00K | $571.00K | $593.00K | $1.20M | $723.00K | 17.8% | -65.8% |
By region
From the segment and revenue-disaggregation notes of Arbutus Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.